Capricor Therapeutics (NASDAQ:CAPR) Stock Price Breaks Below Two Hundred Day Moving Average – Should You Sell?

Capricor Therapeutics, Inc. (NASDAQ:CAPR)’s share price passed below its two hundred day moving average during trading on Thursday. The stock has a two hundred day moving average of $18.77 and traded as low as $5.80. Capricor Therapeutics shares last traded at $6.13, with a volume of 2,748,399 shares changing hands.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the company. JonesTrading downgraded Capricor Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, July 31st. Wall Street Zen downgraded Capricor Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 1st. Weiss Ratings reissued a “sell (d-)” rating on shares of Capricor Therapeutics in a report on Friday, September 11th. Cantor Fitzgerald upgraded shares of Capricor Therapeutics from a “neutral” rating to an “overweight” rating in a research report on Friday, August 14th. Finally, Roth Capital cut shares of Capricor Therapeutics from a “buy” rating to a “neutral” rating and set a $7.00 price target on the stock. in a report on Monday, July 27th. Four analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $30.25.

Capricor Therapeutics Stock Up 4.3%

The firm has a market capitalization of $356.40 million, a P/E ratio of -2.50 and a beta of 0.61. The business’s 50-day simple moving average is $8.22 and its 200 day simple moving average is $18.77.

Capricor Therapeutics (NASDAQ:CAPR) last announced its quarterly earnings data on Thursday, August 13th. The biotechnology company reported ($0.70) earnings per share for the quarter, missing the consensus estimate of ($0.59) by ($0.11). Sell-side analysts predict that Capricor Therapeutics, Inc. will post -1.71 earnings per share for the current year.

Institutional Investors Weigh In On Capricor Therapeutics

Several hedge funds have recently bought and sold shares of the business. SBI Securities Co. Ltd. lifted its position in Capricor Therapeutics by 834.6% in the 3rd quarter. SBI Securities Co. Ltd. now owns 26,310 shares of the biotechnology company’s stock valued at $249,000 after acquiring an additional 23,495 shares in the last quarter. Activest Wealth Management grew its stake in shares of Capricor Therapeutics by 100.0% in the third quarter. Activest Wealth Management now owns 4,000 shares of the biotechnology company’s stock worth $38,000 after acquiring an additional 2,000 shares during the period. Squarepoint Ops LLC raised its holdings in shares of Capricor Therapeutics by 57.8% during the second quarter. Squarepoint Ops LLC now owns 19,731 shares of the biotechnology company’s stock valued at $475,000 after purchasing an additional 7,231 shares during the last quarter. Montanova Capital LLC raised its holdings in shares of Capricor Therapeutics by 7.2% during the second quarter. Montanova Capital LLC now owns 4,092,784 shares of the biotechnology company’s stock valued at $98,554,000 after purchasing an additional 274,184 shares during the last quarter. Finally, Bank of New York Mellon Corp bought a new position in Capricor Therapeutics during the second quarter valued at approximately $3,895,000. Institutional investors own 21.68% of the company’s stock.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc is a biotechnology company focused on developing cell and exosome-based therapies for serious diseases. The company’s research and development programs are designed to address conditions involving muscle degeneration, inflammation and tissue damage.

Capricor’s lead investigational product is deramiocel, also known as CAP-1002, an allogeneic cardiac-derived cell therapy being developed for Duchenne muscular dystrophy. The company has also developed an exosome-based technology platform intended to support the delivery of therapeutic proteins, nucleic acids and other biological materials.

Founded in 2005, Capricor is headquartered in San Diego, California, and conducts its development activities primarily in the United States while working with research, clinical and commercial partners.